pTwist-SARS-CoV-2 Δ18 B.1.617.2v1 Citations (4)

Originally described in: mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Roederer AL, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB Cell. 2022 Jan 6. pii: S0092-8674(21)01496-3. doi: 10.1016/j.cell.2021.12.033. PubMed Journal

---

Articles Citing pTwist-SARS-CoV-2 Δ18 B.1.617.2v1

Articles
PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. Biomacromolecules. 2022 Sep 12;23(9):3535-3548. doi: 10.1021/acs.biomac.2c00271. Epub 2022 Aug 2. PubMed
Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Ho HPT, Vo DNK, Lin TY, Hung JN, Chiu YH, Tsai MH. Biomed Pharmacother. 2022 Nov;155:113766. doi: 10.1016/j.biopha.2022.113766. Epub 2022 Sep 28. PubMed
High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies. Rocha VPC, Machado BAS, Quadros HC, Fernandes AMS, Fiuza BSD, Meira CS, da Silva VTB, Evangelista AF, Fonseca LMDS, Badaro RJDS, Soares MBP. Vaccines (Basel). 2024 Feb 24;12(3):236. doi: 10.3390/vaccines12030236. PubMed
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells. Antia A, Alvarado DM, Zeng Q, Casorla-Perez LA, Davis DL, Sonnek NM, Ciorba MA, Ding S. Viruses. 2024 Apr 19;16(4):634. doi: 10.3390/v16040634. PubMed

If you have published an article using this material, please email us at to have your article added to this page.